A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 9, Issue 2, 2009, Pages 154-159

  Kodama, Tomoko ^a   Abe, Masahiro ^b   Iida, Shinsuke ^c   Ozaki, Shuji ^b   Sakai, Akira ^d   Sawamura, Morio ^e   Shimazaki, Chihiro ^f   Miyata, Akira ^g   Wakayama, Toshio ^h   Murakami, Hirokazu ^a  

^a GUNMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e Shibukawa Medical Center   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g CHUGOKU CENTRAL HOSPITAL   (Japan)

^h SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Angiogenesis; Dexamethasone; M protein; Plasma trough concentration

Indexed keywords

DEXAMETHASONE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; BLOOD; DOSE RESPONSE; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 67650698311     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.037     Document Type: Article

References (28)

1. Attal M, Harousseau J-L, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-502.
2. Lenz W. Thalidomide embryopathy in Germany, 1959-1961. Prog Clin Biol Res 1985; 163C:77-83.
3. Lu J, Palmer BD, Kestell P, et al. Thalidomide metabolism in mice and patients with multiple myeloma. Clin Cancer Res 2003; 9:1680-8.
4. Ando Y, Fuse E, Figg W. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002; 8:1964-73.
5. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-5.
6. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87:503-8.
7. Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38:250-9.
8. Figg WD, Raje S, Bauer KS, et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 1999; 88:121-5.
9. Simmons BR, Lush RM, Figg WD. A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. Anal Chim Acta 1997; 339:91-7.
10. Durie BG. Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol 2002; 29(suppl 17):34-8.
11. Johnston RE, Abdalla SH. Thalidomide in low doses in effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 2002; 43:351-4.
12. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003; 25:342-95.
13. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory myeloma. Ann Oncol 2001; 12:991-5.
14. Wang M, Weber DM, Delasalle K, et al. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005; 79:194-7.
15. Shaughnessy J, Zhan F, Tian E, et al. Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. Blood 2000; 96:(Abstract 485).
16. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-50.
17. Palumbo A, Falco P, Ambrosini MT, et al. Thalodomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol 2005; 75:391-5.
18. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-23.
19. Myers B, Grimley C, Dolan G. Thalidomide and low-dose dexamethasone in myeloma treatment. Br J Haematol 2001; 114:245.
20. Tiplady CW, Summerfield GP. Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2000; 111:381.
21. Faigle JW, Keberle H, Riess W, et al. The metabolic fate of thalidomide. Experientia 1962; 18:389-432.
22. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965; 25:338-51.
23. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 1965; 25:324-37.
24. Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 1986; 82:175-9.
25. Price DK, Ando Y, Kruger EA, et al. 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monit 2002; 24:104-10.
26. Marks MG, Shi J, Fry MO, et al. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull 2002; 25:597-604.
27. Kodama T, Horiuchi R, Tsukamoto N, et al. Unstable thalidomide concentration in patients with refractory anemia. Lab Hematol 2004; 10:132-6.
28. Raje N, Anderson K. Thalidomide--a revival story. N Engl J Med 1999; 341:1606-9.